Streetbeat News

Products Services

ETHE

IBIT

Bitcoin experienced a 2.3% decline to $64,500 despite significant inflows into Bitcoin spot ETFs, particularly from BlackRock and Grayscale. Ethereum also saw a decline, with substantial outflows from its ETFs. The broader cryptocurrency market showed weakness, but long-term prospects remain optimistic.

Portfolio Pulse from Murtuza Merchant

August 01, 2024 | 11:52 am

PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) has aligned with the FDA on the next steps for its Phase 3 VERSATILE-003 trial targeting HPV16-positive head and neck cancer. The trial is set to begin in Q4 2024. A conference call will be held today at 8:00 a.m. ET to discuss the details.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:51 am

TNXP

Tonix Pharmaceuticals (NASDAQ:TNXP) has received FDA Fast Track designation for its fibromyalgia treatment, TNX-102 SL. This designation facilitates the development and review process, potentially bringing the drug to market sooner. TNX-102 SL has shown significant improvements in fibromyalgia symptoms in Phase 3 trials and is well tolerated. Tonix plans to submit a New Drug Application (NDA) in the second half of the year and may request Priority Review.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:49 am

BA

Boeing's defense, space, and security segment reported a $913 million loss in Q2, with overall revenues dipping 15% to $16.87 billion. The losses are attributed to delays in the Starliner spacecraft and other fixed-price programs. Boeing's stock closed up 2% at $190.6 but is down 24.3% year-to-date.

Portfolio Pulse from Anan Ashraf

August 01, 2024 | 11:49 am

ALXO

ALX Oncology Holdings shares are trading lower following the announcement of topline data from its ASPEN-06 Phase 2 trial.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:49 am

RDHL

RedHill Biopharma shares are trading higher after the company announced a new publication showing that triple antimicrobial therapy with RHB-104 plus standard of care is 64% more effective than standard of care alone in treating Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:45 am

RDHL

RedHill Biopharma announced new data showing that its triple antimicrobial therapy RHB-104, combined with standard care, is 64% more effective than standard care alone in treating Crohn's disease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:43 am

ACB

Aurora Cannabis and Vectura Fertin Pharma have announced a commercial collaboration with Cogent International Manufacturing to launch a CBD lozenge on Aurora's Canadian medical cannabis platform. The agreement has an initial term of 24 months, with the first product expected to launch in late 2024.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:40 am

AER

AerCap has delivered the first three of fifteen new Airbus A321neo aircraft to AirAsia on a long-term lease.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 11:17 am

PASG

Passage Bio (NASDAQ:PASG) has out-licensed three pediatric lysosomal storage disease programs to GEMMA Biotherapeutics for $20M in initial payments and up to $114M in milestones, plus future royalties. GEMMABio will assume financial obligations and Passage Bio will support the transition.

Portfolio Pulse from charles@benzinga.com

August 01, 2024 | 11:13 am